Identification and Characterization of Positively Selected Mutations in Nef of Four HIV-1 Major Subtypes from Los Alamos National Laboratory

Author(s): Elnaz Shadabi, Binhua Liang, Frank Plummer, Ma Luo*

Journal Name: Current HIV Research

Volume 16 , Issue 2 , 2018


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Human immunodeficiency virus-1 (HIV-1) mutates rapidly to escape host immune pressure. This results in the generation of positively selected mutations (PSM) throughout the viral genome. Escape mutations in Nef, one of the accessory proteins of HIV-1, which plays an important role in viral pathogenicity have previously been identified in several large cohort studies, but the evolution of PSMs overtime in various HIV-1 subtypes remains unknown.

Methods: 161 clade A1, 3093 clade B, 647 clade C and 115 clade D HIV-1 nef sequences were obtained from the HIV Database of Los Alamos National Laboratory and aligned using MEGA 6.0. The sequences from each clade were grouped based on the year of collection. Quasi analysis was used to identify PSMs and the number and locations of PSMs were compared among different subtypes.

Results: PSMs for all four subtypes were distributed across the sequence of Nef, and conserved residues F90, W113, PxxPxR (a.a 72-77) remain unaltered overtime. The frequency of PSMs was stable among subtype B sequences but increased overtime for other subtypes. Phylogenetic analysis shows that sequences containing PSMs tend to cluster together at both inter and intra- subtype levels.

Conclusion: Identification of PSMs and their changes overtime within various subtypes of HIV-1 is important in defining global viral evolutionary patterns that can provide insights for designing therapeutic strategies.

Keywords: HIV-1 Nef, subtype, positive selection, evolution, PSMs, mutations.

[1]
Becerra JC, Bildstein LS, Gach JS. Recent Insights into the HIV/ AIDS Pandemic. Microb Cell 2016; 3: 451-75.
[2]
Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 19-42.
[3]
Kiwanuka N, Laeyendecker O, Quinn TC, et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS 2009; 23: 2479-84.
[4]
Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2: e112.
[5]
Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195: 1177-80.
[6]
Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197: 707-13.
[7]
Butler IF, Pandrea I, Marx PA, Apetrei C. HIV genetic diversity: biological and public health consequences. Curr HIV Res 2007; 5: 23-45.
[8]
Carlson JM, Le AQ, Shahid A. Brumme ZL. HIV-1 adaptation to HLA: A window into virus–host immune interactions. Trends Microbiol 2015; 23(4): 212-24.
[9]
Gao F, Korber BT, Weaver E, Liao H-X, Hahn BH, Haynes BF. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004; 3: S161-8.
[10]
Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007; 3: e94.
[11]
Pan C, Kim J, Chen L, Wang Q, Lee C. The HIV positive selection mutation database. Nucleic Acids Res 2007; 35: D371-5.
[12]
Liang B, Luo M, Ball TB, Jones SJM, Plummer FA. QUASI analysis of host immune responses to Gag polyproteins of human immunodeficiency virus type 1 by a systematic bioinformatics approach. Biochem Cell Biol 2010; 88: 671-81.
[13]
Liang B, Luo M, Ball TB, Plummer FA. QUASI analysis of the HIV-1 envelope sequences in the Los Alamos National Laboratory HIV sequence database: pattern and distribution of positive selection sites and their frequencies over years. Biochem Cell Biol 2007; 85: 259-64.
[14]
Geyer M, Fackler OT, Peterlin BM. Structure--function relationships in HIV-1 Nef. EMBO Rep 2001; 2: 580-5.
[15]
Ren X, Park SY, Bonifacino JS, Hurley JH. How HIV-1 Nef hijacks the AP-2 clathrin adaptor to downregulate CD4. eLife 2014; 3: e01754.
[16]
Mwimanzi P, Markle TJ, Ueno T, Brockman MA. Human Leukocyte Antigen (HLA) Class I Down-Regulation by Human Immunodeficiency Virus Type 1 Negative Factor (HIV-1 Nef): What Might We Learn From Natural Sequence Variants? Viruses 2012; 4: 1711-30.
[17]
Saksela K, Cheng G, Baltimore D. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 1995; 14: 484-91.
[18]
Stolp B, Abraham L, Rudolph JM, Fackler OT. Lentiviral Nef proteins utilize PAK2-mediated deregulation of cofilin as a general strategy to interfere with actin remodeling. J Virol 2010; 84: 3935-48.
[19]
Das SR, Jameel S. Biology of the HIV Nef protein. Indian J Med Res 2005; 121: 315-32.
[20]
Adland E, Carlson JM, Paioni P, et al. Nef-specific CD8+ T cell responses contribute to HIV-1 immune control. PLoS One 2013; 8: e73117.
[21]
Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009; 4: e6687.
[22]
Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94: 1890-5.
[23]
Stewart JJ, Watts P, Litwin S. An algorithm for mapping positively selected members of quasispecies-type viruses. BMC Bioinformatics 2001; 2: 1.
[24]
Merani S, Petrovic D, James I, et al. Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak. Hepatology 2011; 53: 396-405.
[25]
Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10: 512-26.
[26]
Raney A, Shaw AY, Foster JL, Garcia JV. Structural constraints on human immunodeficiency virus type 1 Nef function. J Virol 2007; 368: 7-16.
[27]
Khan IH, Sawai ET, Antonio E, et al. Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques. J Virol 1998; 72: 5820-30.
[28]
Agopian K, Wei BL, Garcia JV, Gabuzda D. A Hydrophobic Binding Surface on the Human Immunodeficiency Virus Type 1 Nef Core Is Critical for Association with p21-Activated Kinase 2. J Virol 2006; 80: 3050-61.
[29]
Bordo D, Argos P. Suggestions for “safe” residue substitutions in site-directed mutagenesis. J Mol Biol 1991; 217: 721-9.
[30]
Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81: 10209-19.
[31]
Lee CH, Saksela K, Mirza UA, Chait BT, Kuriyan J. Crystal Structure of the Conserved Core ofHIV-1 Nef Complexed with a Src Family SH3 Domain 1997. 1-12.
[32]
Mwimanzi P, Hasan Z, Tokunaga M, Gatanaga H, Oka S, Ueno T. Naturally arising HIV-1 Nef variants conferring escape from cytotoxic T lymphocytes influence viral entry co-receptor expression and susceptibility to superinfection. Biochem Biophys Res Commun 2010; 403: 422-7.
[33]
Piguet V, Gu F, Foti M, et al. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 1999; 97: 63-73.
[34]
Carl S, Iafrate AJ, Lang SM, et al. Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol 2000; 74: 4155-64.
[35]
Lang SM, Iafrate AJ, Stahl-Hennig C, et al. Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques. Nat Med 1997; 3: 860-5.
[36]
Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Sci 2002; 296: 1439-43.
[37]
Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197: 563-71.
[38]
Chikata T, Carlson JM, Tamura Y, et al. Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. J Virol 2014; 88: 4764-75.
[39]
Roider J, Kalteis A-L, Vollbrecht T, et al. Adaptation of CD8 T cell responses to changing HIV-1 sequences in a cohort of HIV-1 infected individuals not selected for a certain HLA allele. PLoS One 2013; 8: e80045.
[40]
Kløverpris HN, Leslie A, Goulder P. Role of HLA Adaptation in HIV Evolution. Front Immunol 2015; 6: 665.
[41]
Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80: 3617-23.
[42]
Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009; 5: e1000365.
[43]
Gijsbers EF, Feenstra KA, van Nuenen AC, et al. HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag. PLoS One 2013; 8: e81235-10.
[44]
Alter I, Gragert L, Fingerson S, Maiers M, Louzoun Y. HLA class I haplotype diversity is consistent with selection for frequent existing haplotypes. PLOS Comput Biol 2017; 13: e1005693.
[45]
Isitman G, Stratov I, Kent SJ. Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol 2012; 2012: 637208-8.
[46]
Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et al. Influence of HLA-C Expression Level on HIV Control. Sci 2013; 340: 87-91.
[47]
Wang Z, Liu H-W, Hong K-X, Yu Z-J, Chen J-P, Ruan Y-H, et al. Complete human immunodeficiency virus-1 specific T lymphocyte response to Chinese human immunodeficiency virus-1 B/C chronic infectors. Biomed Environ Sci 2009; 22: 522-8.
[48]
Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreño J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 2011; 9: 208.
[49]
Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, et al. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One 2013; 8: e64405.
[50]
Bernardin F, Kong D, Peddada L, Baxter-Lowe LA, Delwart E. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol 2005; 79: 11523-8.
[51]
Ranki A, Nyberg M, Ovod V, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 1995; 9: 1001-8.
[52]
Kaufmann DE, Bailey PM, Sidney J, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 2004; 78: 4463-77.
[53]
Fonseca SG, Coutinho-Silva A, Fonseca LAM, et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS 2006; 20: 2263-73.
[54]
Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193: 169-80.
[55]
Kitano M, Kobayashi N, Kawashima Y, et al. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect 2008; 10: 764-72.
[56]
Piguet V, Trono D. The Nef protein of primate lentiviruses. Rev Med Virol 1999; 9: 111-20.
[57]
Li T, Steede NK, Nguyen H-NP, et al. Comprehensive analysis of contributions from protein conformational stability and major histocompatibility complex class II-peptide binding affinity to CD4+ epitope immunogenicity in HIV-1 envelope glycoprotein. J Virol 2014; 88: 9605-15.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2018
Published on: 15 August, 2018
Page: [130 - 142]
Pages: 13
DOI: 10.2174/1570162X16666180330140807
Price: $65

Article Metrics

PDF: 28
HTML: 4